INDOCYANINE GREEN FOR INJECTION, USP POWDER FOR SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

INDOCYANINE GREEN

Pieejams no:

DIAGNOSTIC GREEN LIMITED

ATĶ kods:

V04CX01

SNN (starptautisko nepatentēto nosaukumu):

INDOCYANINE GREEN

Deva:

25MG

Zāļu forma:

POWDER FOR SOLUTION

Kompozīcija:

INDOCYANINE GREEN 25MG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

15G/50G

Receptes veids:

Ethical

Ārstniecības joma:

CARDIAC FUNCTION

Produktu pārskats:

Active ingredient group (AIG) number: 0150962001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2019-02-15

Produkta apraksts

_Indocyanine Green for Injection, USP Product Monograph _
_Page 1 of 14 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Indocyanine Green for Injection, USP
Lyophilized green powder containing 25 mg of indocyanine green,
Intravenous Injection
Diagnostic Agent
Imported and Distributed By:
Seaford Pharmaceuticals Inc.
28-1530 Drew Road
Mississauga Ontario
Canada L5S 1W8
Date of Initial Approval:
FEB 15, 2019
Date of Revision:
June 30, 2021
Marketing Authorization Holder:
Diagnostic Green GmbH
Otto-Hahn-Straße 20
85609 Aschheim-Dornach
Bavaria, Germany
Submission Control No: 248253
_Indocyanine Green for Injection, USP Product Monograph _
_Page 2 of 14 _
TABLE OF CONTENTS
TABLE OF CONTENTS
......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... 3
1
INDICATIONS ..........................................................................................................
3
1.1
Pediatrics...........................................................................................................
3
1.2
Geriatrics...........................................................................................................
3
2
CONTRAINDICATIONS ..........................................................................................
3
3
DOSAGE AND ADMINISTRATION ........................................................................
3
3.1
Recommended Dose and Dosage Adjustment
..................................................... 3
3.1.1
Indicator-Dilution Studies
...............................................................................
3
3.1.2
Hepatic Function Studies
................................................................................
4
3.1.3
Ophthalmic Angiography
Studies....................................................................
7
4
OVERDOSAGE .....................................................................................................